Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Standard Optimization of Autologous Stem Cells by Intranasal and Intravenous Administration to Treat Parkinson's Disease and Atypical Parkinsonism

NCT06858254 is registered in ClinicalTrials.gov with Apeiron Research Center as lead sponsor.

NCT NCT06858254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06858254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Standard Optimization of Autologous Stem Cells by Intranasal and Intravenous Administration to Treat Parkinson's Disease and Atypical Parkinsonism
Lead sponsor
Apeiron Research Center
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
April 1, 2025
Completion date
April 30, 2028
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atypical parkinsonism, parkinson disease (pd)